Dyslipidemia

Depressed elderly patients undergoing SAVR or TAVR had a 7.3% higher rate of mortality compared to non-depressed patients.

Researchers have found distinctions between calcific aortic valve disease and atherosclerosis that could lead to improved care.

Varenicline (Chantix) increases patients’ risk of an emergency department visit or hospitalization for a cardiovascular event by 34%.

The intravenous infusion therapy is designed to increase blood pressure in adult patients with hypotension.

Study data showed that 38% of HIV-seropositive women were using statins while guidelines recommend that 45% should be.

Kevin Maki, PhD, discussed the impact that the new guidelines for hypertension from the AHA and the ACC will have on patients and physicians.

Renova Therapeutics is planning a 536-patient phase 3 trial, FLOURISH, to begin in early 2018.

Kevin Maki, PhD, discussed the current state of lipid care in the United States.

Kevin Maki, PhD, discussed weighing the benefits of PCSK9 inhibitors against their high price tag.

The study found that 5.6% of all incident cancers from 5 years ago were attributable to the combined effects of diabetes and high BMI.

OZEMPIC, a GLP-1 receptor agonist, was tested in 2-year cardiovascular outcome trials.

The projection based study found strong correlations between childhood and adulthood obesity.

After being granted a Priority Review designation, the PCSK9 inhibitor has been approved for risk reduction of heart attack, stroke, and coronary revascularization.

The smart strap is the first medical accessory for a smartwatch to receive FDA approval.

James Underberg, MD, President-Elect of the National Lipid Association, Clinical Assistant Professor of Medicine, NYU School of Medicine, NYU Center for the Prevention of Cardiovascular Disease, discusses statin intolerance and the future of cholesterol treatments.

Quick Quiz: Which antiplatelet/antithrombin combination provides greatest efficacy with least risk for bleeding?